What are the side effects of nipocalimab breakthrough therapy designation BTD?
•
4 min read
According to clinical trial data, the most common adverse reactions reported in at least 10% of patients treated with nipocalimab breakthrough therapy designation BTD were respiratory tract infection, peripheral edema, and muscle spasms. This FcRn inhibitor is under evaluation for several autoimmune and alloimmune conditions, making a review of its safety profile essential.
